---
title: "JILIN AODONG: Yanbian Pharmaceutical passed the drug GMP compliance inspection"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/227720645.md"
description: "According to the Zhitong Finance APP, JILIN AODONG announced that its holding subsidiary JILIN AODONG Yanbian Pharmaceutical Co., Ltd. (referred to as \"Yanbian Pharmaceutical\") has received the \"Drug GMP Compliance Inspection Notification\" approved and issued by the Jilin Provincial Drug Administration"
datetime: "2025-02-10T09:21:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/227720645.md)
  - [en](https://longbridge.com/en/news/227720645.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/227720645.md)
generator: "portal-rs"
---

# JILIN AODONG: Yanbian Pharmaceutical passed the drug GMP compliance inspection

According to the Zhitong Finance APP, JILIN AODONG (000623.SZ) announced that its holding subsidiary JILIN AODONG YANBIAN PHARMACEUTICAL CO., LTD. (referred to as "Yanbian Pharmaceutical") has received the "Drug GMP Compliance Inspection Notice" approved and issued by the Jilin Provincial Drug Administration

### Related Stocks

- [000623.CN](https://longbridge.com/en/quote/000623.CN.md)

## Related News & Research

- [Pondy Oxides And Chemicals Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected](https://longbridge.com/en/news/305560101.md)
- [Alkem Laboratories Limited (NSE:ALKEM) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates](https://longbridge.com/en/news/305559747.md)
- [RioCan Real Estate Investment Trust (TSX:REI.UN) Expands Its Buyback Program, Is It Still Undervalued?](https://longbridge.com/en/news/305557624.md)
- [Kava Lend loses roughly $3.8 million to hack, sending KAVA token down nearly 40%](https://longbridge.com/en/news/305556359.md)
- [HONGQI EHS4 Set for Global Debut in Venice: Eastern Elegance Arrives in Europe](https://longbridge.com/en/news/305555184.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**